Glenmark gets USFDA nod for skin ointment
New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for Tacrolimus ointment used for treating atopic dermatitis (eczema).
Glenmark Pharmaceuticals Inc USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Tacrolimus ointment USP, 0.1 percent, the company said in a BSE filing.
The product is a generic version of Protopic ointment of Leo Pharma AS in the same strength. According to IQVIA sales data for the 12-month period ended February 2018, Protopic ointment 0.1 percent achieved annual sales of around $109 million, Glenmark Pharmaceuticals said.
The company’s current portfolio consists of 132 products authorised for distribution in the US market and 61 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd